FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC
The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
James Breitmeyer Onct 534 Patients With Relapsed Refractory Metastatic Castration Resistant Prostate Cancer Onct 534 101 Trial
Source: onclive.com